These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21893442)

  • 1. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
    Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
    Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 mutations across a spectrum of venous thrombosis cases.
    Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
    Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
    Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
    Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
    De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
    J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation.
    Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M
    Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418
    [No Abstract]   [Full Text] [Related]  

  • 8. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis.
    Colaizzo D; Tiscia GL; Bafunno V; Amitrano L; Vergura P; Lupone MR; Grandone E; Guardascione MA; Margaglione M
    Thromb Res; 2011 Sep; 128(3):233-6. PubMed ID: 21497883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
    Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
    Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings.
    Colaizzo D; Amitrano L; Iannaccone L; Vergura P; Cappucci F; Grandone E; Guardascione MA; Margaglione M
    J Med Genet; 2007 Jun; 44(6):412-6. PubMed ID: 17307838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
    Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
    Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
    [No Abstract]   [Full Text] [Related]  

  • 14. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
    De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
    Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
    Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
    Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
    Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
    J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
    Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
    Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
    [No Abstract]   [Full Text] [Related]  

  • 18. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.
    Orr DW; Patel RK; Lea NC; Westbrook RH; O'Grady JG; Heaton ND; Pagliuca A; Mufti GJ; Heneghan MA
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1330-6. PubMed ID: 20331577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
    Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
    Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.
    Owens CD
    J Vasc Surg; 2010 Jul; 52(1):205-7. PubMed ID: 20434300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.